Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

development strategy for picoplatin, including Howard A. Burris, III, M.D., of The Sarah Cannon Research Institute in Nashville; E. David Crawford, M.D., of the University of Colorado Comprehensive Cancer Center; Robert F. Ozols, M.D., Ph.D., of the Fox Chase Cancer Center in Philadelphia; and Everett E. Vokes, M.D., of the University of Chicago Pritzker School of Medicine. Management Appointment

-- Appointed Janet R. Rea, MSPH, RAC, as vice president, regulatory affairs and quality, to execute regulatory and quality activities with the FDA and other regulatory authorities in support of our targeted commercial launch of picoplatin.

Second Quarter 2008 Unaudited Financial Results

The Company reported a net loss of $12.5 million ($0.36 diluted loss per share on a loss applicable to common shares of $12.7 million) for the second quarter of 2008 compared to a net loss of $8.5 million ($0.28 diluted loss per share on a loss applicable to common shares of $8.7 million) for the second quarter of 2007.

There was no revenue in either of the second quarters of 2008 or 2007.

Total operating expenses for the second quarter of 2008 increased 40 percent to $12.9 million, from $9.2 million for the second quarter of 2007, and increased 37 percent to $23.4 million for the six months ended June 30, 2008, from $17.1 million for the same period in 2007.

Research and development (R&D) expenses increased 57 percent to $9.2 million for the second quarter of 2008, from $5.8 million for the second quarter of 2007. R&D expenses increased 37 percent to $15.5 million for the six months ended June 30, 2008, from $11.3 million for the same period in 2007. The increase in R&D expenses for the three and six months ended June 30, 2008 resulted primarily from increased costs associated with our picoplatin trials and pre-clinical programs.

General and administrative (G&A) expenses increased 10 percent to $3.7 million for the second quarter of 2008, fr
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for Disease Control ... , and the Multicultural AIDS Coalition $3.78 million for a five-year HIV ... with men (MSM) and transgender women, the groups at highest risk of HIV ...
(Date:7/7/2015)... MD (PRWEB) , ... July 07, 2015 , ... SC&H ... of Service, which aims to give back to the community through company-wide volunteering efforts. ... from SC&H Group dedicate the day to assisting those in need throughout Baltimore and ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... to further enhance the experience for its patient community using its IDF ePHR, ... allows patients with primary immunodeficiency diseases (PI) to easily track their health information, ...
(Date:7/7/2015)... ... July 07, 2015 , ... FSAstore.com today announced the ... HSA holders. HSAstore.com makes it simple to use, spend and manage HSA funds with ... their accounts. , According to a report by Devenir , approximately 13.8 ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... America ... others. California Casualty’s Nominate A Hero program offers a special way to ... a well-deserving hero receives a $250 gift card and their place on the “Wall ...
Breaking Medicine News(10 mins):Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2
... Joint Commission,International (JCI) today announced its accreditation by ... is a division of Joint Commission,Resources, Inc. (JCR), ... JCI is a global leader in health care ... hospitals in 27 countries. This external,endorsement by ISQua ...
... Jan. 2 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced ... JPMorgan Healthcare Conference on Wednesday, January 9, 2008 at,approximately ... is scheduled to be webcast live and may be ... Gen-Probe,s website at, http://www.gen-probe.com . The webcast will be ...
... opioids more often than blacks, Hispanics , , WEDNESDAY, Jan. 2 ... in significant pain, you are less likely to be prescribed ... white, new research shows. , The reasons for the disparity ... effective pain treatment in the ER as often as whites ...
... Study undercuts notion that they,re given to help the poor, ... Most free drug samples go to wealthy and insured patients, ... most, Harvard researchers report. , In fact, more than four-fifths ... one-fifth are uninsured and less than one-third have low incomes ...
... Il-22 gene delivers the goods and decreases intestinal ... inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative ... factor IL-22 can have both IBD promoting and IBD ... Massachusetts General Hospital, Boston, have established that IL-22 ameliorates ...
... a non-invasive way to determine the existence and extent ... of pharmacologic strategies to combat the condition. These findings ... published by John Wiley & Sons on behalf of ... (AASLD). The article is also available online at Wiley ...
Cached Medicine News:Health News:Joint Commission International Achieves Accreditation from ISQua 2Health News:Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference 2Health News:Minorities Less Likely to Get Powerful Painkillers in ER 2Health News:Minorities Less Likely to Get Powerful Painkillers in ER 3Health News:Most Free Drug Samples Go to Wealthy and Insured 2Health News:Most Free Drug Samples Go to Wealthy and Insured 3Health News:JCI online early table of contents: Jan. 2, 2008 2Health News:JCI online early table of contents: Jan. 2, 2008 3Health News:JCI online early table of contents: Jan. 2, 2008 4Health News:JCI online early table of contents: Jan. 2, 2008 5Health News:JCI online early table of contents: Jan. 2, 2008 6Health News:JCI online early table of contents: Jan. 2, 2008 7Health News:JCI online early table of contents: Jan. 2, 2008 8Health News:JCI online early table of contents: Jan. 2, 2008 9Health News:MRI techniques evolving towards better assessment of liver fibrosis 2
(Date:7/7/2015)... NEW YORK , July 7, 2015 ... new generation of drugs within human and veterinary oncology, ... the Securities and Exchange Commission, in connection with the ... the NASDAQ Stock Market. The number of American Depositary ... price range for the offering have not yet been ...
(Date:7/7/2015)... July 7, 2015  Monopar Therapeutics LLC, an emerging ... that its co-founder and CEO, Chandler D. Robinson ... U.K. Alumni Entrepreneurial Award. The British Council selected one ... India , and the ... made by entrepreneurs who have leveraged their U.K. education ...
(Date:7/7/2015)... DIEGO , July 7, 2015   ... announced today initiation of enrollment and dosing of ... study of ABX-1431, a first-in-class, investigational endocannabinoid system ... platform, which finds new small molecule drug candidates ... enzymes with important regulatory roles in human physiology ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
... SUNNYVALE, Calif., Oct. 19, 2011 ... premier radiation oncology company, announced today that it ranked 274th ... growing technology, media, telecommunications, life sciences and clean technology companies ... based on percentage fiscal year revenue growth from 2006 to ...
... therapy games can help people with Parkinson,s disease improve their ... by the UCSF School of Nursing and Red Hill Studios, ... the subjects in the three-month research project showed small improvements ... and Red Hill were the first research team in the ...
Cached Medicine Technology:Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3Accuray Ranked 274th Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 4Red Hill Studios and UCSF Announce Computer Games Help People with Parkinson's Disease 2Red Hill Studios and UCSF Announce Computer Games Help People with Parkinson's Disease 3
Facial Mask...
Deluxe Abdominal Binders...
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from ...
Ideal for abdominal and flank procedures....
Medicine Products: